Oncopeptides AB (publ)

OM:ONCO Stock Report

Market Cap: SEK 1.5b

Oncopeptides Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OM:ONCO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
26 Aug 25BuySEK 250,008Sofia HeigisIndividual56,820SEK 4.40

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ONCO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,916,4930.703%
VC/PE Firms41,410,73115.2%
Institutions45,303,15916.6%
General Public184,075,97467.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.7%.

Top Shareholders

Top 21 shareholders own 34.12% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.2%
Odlander, Fredrikson & Co. AB
41,410,731SEK 229.4m0%21.4%
5.08%
Avanza Fonder AB
13,854,564SEK 76.8m67.2%0.06%
3.9%
Redmile Group, LLC
10,635,201SEK 58.9m0%0.41%
3.83%
Nordnet Pensionsförsäkring AB
10,438,896SEK 57.8m0%0.71%
3.04%
Industrifonden
8,285,258SEK 45.9m0%43.74%
1.46%
Handelsbanken Asset Management
3,977,463SEK 22.0m0%no data
0.47%
Per Wold-Olsen
1,271,107SEK 7.0m25%no data
0.39%
SEB Investment Management AB
1,068,552SEK 5.9m0%no data
0.28%
FCG Fonder AB
763,012SEK 4.2m0%0.04%
0.19%
Storebrand Fonder AB,
526,824SEK 2.9m0%no data
0.1%
Eva Nordström
280,464SEK 1.6m0%no data
0.053%
Sofia Heigis
143,728SEK 796.2k65.4%no data
0.051%
Skandia Fonder AB
140,274SEK 777.2k0%no data
0.037%
Jarl Jungnelius
101,042SEK 559.7k0%no data
0.026%
Cecilia Wennborg
70,824SEK 392.4k0%no data
0.0086%
Henrik Bergentoft
23,332SEK 129.3k0%no data
0.006%
David Augustsson
16,332SEK 90.5k0%no data
0.0037%
State Street Global Advisors, Inc.
9,947SEK 55.1k0%no data
0.0035%
Stefan Norin
9,664SEK 53.5k0%no data
0.0016%
Danske Bank A/S
4,326SEK 24.0k0%no data
0.0015%
DFP Deutsche Finanz Portfolioverwaltung GmbH
4,000SEK 22.2k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/27 07:45
End of Day Share Price 2025/11/27 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncopeptides AB (publ) is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Patrik LingDNB Carnegie
Erik HultgårdDNB Carnegie